2013 Fiscal Year Final Research Report
Development of novel formulation to make possible to multidisciplinary cancer-therapy with anti-cancer drugs, thermic, and immune treatment.
| Project/Area Number |
23659671
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
LEE CHUNMAN 大阪大学, 医学部附属病院, 特任准教授 (10432543)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
EBARA Mitsuhiro 独立法人 物質・材料研究機構, 生体材料センター, 研究員 (10452393)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KANEDA Yasufumi 大阪大学, 大学院医学系研究科, 教授 (10177537)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 呼吸器外科 / 温熱治療 |
|---|
| Research Abstract |
We developed the novel formulation of Hemagglutinating Virus of Japan (HVJ-E) and Glycol Chitosan. This formulation will activate the anti-tumor immunity, and it is easy to add this formulation to the following fiber mesh sheet. Then, we developed the novel nano-fiber sheet including PNIPAAm derivatives, anti-cancer drug, and magnetic substance. We can do the thermal therapy in the cancer treatment by adding the alternating magnetic field. Additionally, we control the drug release from this fiber by turning ON the switch of alternating magnetic field. In the cytotoxicitic assay, this fiber with magnetic field revealed high cytotoxicic activity against human mesothelioma, melanoma, and lung cancer cells. In vivo experiments, this fiber with magnetic field made tumor-bearing mice high body temperature (42-43 degree), and this fiber revealed anti-tumor effect. We expected to achieve the multimodal therapy for the intractable cancer by novel fiber and the alternating magnetic field.
|
